| Name | Title | Contact Details |
|---|
Falcon Pharmaceuticals, Ltd. is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CutisPharma is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Michigan Technology and Research Institute, LLC is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kindeva is a global force in combination drug delivery and manufacturing. Leveraging more than 100 years of innovation, Kindeva provides unrivaled expertise at every stage of pulmonary & nasal, injectable, and transdermal therapy development and manufacturing. Whether determining ideal delivery and dosage or scaling sterile manufacturing and fill-finish operations, every solution is backed by extensive technological capabilities, deep regulatory knowledge, and nine state-of-the-art facilities. Kindeva`s proactive, informed solutions minimize risk and maximize confidence from ideation through commercialization, bringing high-quality products to patients in need, faster.
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.